Dengue Fever
To view the entire topic, please log in or purchase a subscription.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Explore these free sample topics:
-- The first section of this topic is shown below --
Basics
Description
- Dengue fever occurs secondary to dengue viral infection
- Most prevalent mosquito-borne viral infection
- Poorly understood immunopathologic response causes dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)
- DHF and DSS usually occur in patients with previous exposure to dengue virus
- Hemorrhagic manifestations occur after defervescence of fever
- Vascular permeability increases
- Plasma extravasates into extravascular space, including pleural and abdominal cavities
- Dengue fever, DHF, and DSS
- World Health Organization – required criteria for the diagnosis of DHF:
- Fever
- Bleeding evidenced by one of the following: Positive tourniquet test, petechiae, ecchymosis, purpura, GI tract bleeding, injection site bleeding
- Increased vascular permeability and plasma leakage as evidenced by an elevated hematocrit (>20%), decreased hematocrit >20% after volume replacement or pleural effusions, ascites or hypoproteinemia
- Thrombocytopenia (<100,000/mm3)
- World Health Organization – required criteria for diagnosis of DSS:
- All 4 criteria of DHF +
- Rapid and weak pulse
- Narrow pulse pressure or hypotension for age
- Cold, clammy skin
- Restlessness
- A vaccine is under development
Etiology
- Occurs in tropical and subtropical regions: Asia, Africa, Central and South America, and the Caribbean
- Caused by dengue virus serotypes 1–4. A fifth serotype was identified in 2013
- Transmitted by mosquitoes: Aedes aegypti and Aedes albopictus
- Incubation period of 3–14 d
- There is only transient and poor cross protection among the 4 serotypes
- Up to 390 million infections occur per year with nearly 100 million resulting in illness
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Basics
Description
- Dengue fever occurs secondary to dengue viral infection
- Most prevalent mosquito-borne viral infection
- Poorly understood immunopathologic response causes dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)
- DHF and DSS usually occur in patients with previous exposure to dengue virus
- Hemorrhagic manifestations occur after defervescence of fever
- Vascular permeability increases
- Plasma extravasates into extravascular space, including pleural and abdominal cavities
- Dengue fever, DHF, and DSS
- World Health Organization – required criteria for the diagnosis of DHF:
- Fever
- Bleeding evidenced by one of the following: Positive tourniquet test, petechiae, ecchymosis, purpura, GI tract bleeding, injection site bleeding
- Increased vascular permeability and plasma leakage as evidenced by an elevated hematocrit (>20%), decreased hematocrit >20% after volume replacement or pleural effusions, ascites or hypoproteinemia
- Thrombocytopenia (<100,000/mm3)
- World Health Organization – required criteria for diagnosis of DSS:
- All 4 criteria of DHF +
- Rapid and weak pulse
- Narrow pulse pressure or hypotension for age
- Cold, clammy skin
- Restlessness
- A vaccine is under development
Etiology
- Occurs in tropical and subtropical regions: Asia, Africa, Central and South America, and the Caribbean
- Caused by dengue virus serotypes 1–4. A fifth serotype was identified in 2013
- Transmitted by mosquitoes: Aedes aegypti and Aedes albopictus
- Incubation period of 3–14 d
- There is only transient and poor cross protection among the 4 serotypes
- Up to 390 million infections occur per year with nearly 100 million resulting in illness
There's more to see -- the rest of this topic is available only to subscribers.